

# The World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition

<https://marketpublishers.com/r/WB4D796FFE8EN.html>

Date: May 2009

Pages: 280

Price: US\$ 3,995.00 (Single User License)

ID: WB4D796FFE8EN

## Abstracts

Worldwide cancer affects more than 10 million people each year. This number is expected to increase by 2.4% by 2020 to 14 million each year. Worldwide approximately 22 million people are living with cancer and nearly 7 million people die. The most common cancers affecting the world include lung, breast, colon/rectum, stomach, liver, prostate, cervical, esophageal, and bladder.

This Kalorama Information report - *The World Market for Cancer Therapeutics and Biotherapeutics* - focuses on several segments for cancer treatment. The report covers both currently marketed and late stage development cancer products. Revenues for each current market segment were generated using dollar and unit sales for each product. The following approaches to cancer therapeutics are covered in the report:

### **Biotherapeutics**

Monoclonal Antibodies

Interleukins/ Interferons

Kinases and Other Treatments

### **Chemotherapy**

Alkylating Agents

Antimetabolites

Cytotoxic Agents

## Plant Derivatives

### **Hormone Therapy**

#### Corticosteroids

#### Hormone Antagonists/ Antagonists

#### Aromatase Inhibitors

#### SERMS

The report includes **market share by type of cancer** and market share by company for each of the three major segments. It also includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development and/or have significant incidence/mortality rates are profiled. The market segments provide an overview, description of products on the market, list of products in late-stage development, market estimates and forecasts, and competitive analysis of leading providers. The report also includes current issues and trends affecting the industry. **A Primary Research Effort**

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers' level.

### **Coverage of the Most Recent Product and Trends**

The base year for data was 2008. Historical data was provided for the years 2004 through 2007, with forecast data provided for 2009 through 2013. Compound annual growth rates (CAGRs) are provided for the 2004-2008, 2009-2013 and 2004-2013 periods for each industry segment covered. Competitive analysis is provided for the year 2008. The forecasted market analysis for 2009-2013 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends. Some of the trends that affected this market include the following:

Insurance and Reimbursement

Drug Costs

Personalized Medicine

Alliances, Acquisitions and Licensing Agreements

Alcohol's Affect on Cancer Incidence

Healthy Lifestyles Continue to Show Promise for Cancer Prevention

- Marketing and Distribution Trends

Geographical Trends

Elderly Clinical Trial Involvement

Late-Stage Drug Development Trends

## **Profiles of Twelve Key Competitors**

As part of its comprehensive coverage, the following companies are profiled:

**AstraZeneca** (coverage of Arimidex, Casodex, Faslodex, Zoladex, Iressa, Nolvadex and other products)

**Biogen IDEC** (coverage of Rituxan and other products)

**Bristol-Myers Squibb** (coverage of Erbitux, Taxol, Ixempra, Sprycel and other

products)

**Eli Lilly** (coverage of Alimta, Gemzar and other products)

**Genentech** (coverage of Avastin, Herceptin, Rituxan )

**Johnson & Johnson** (coverage of Doxil, Velcade, Leustatin)

**Merck & Company** (coverage of Zolanza and other products)

**Novartis** (coverage of Femara, Gleevec/Glivec, Tasigna, Sandostatin, Proleukin, Afinitor and other products)

**Pfizer** (coverage of Camptosar and Sutent)

**Roche** (coverage of Xeloda, Avastin, MabThera, Herceptin, Tarceva and pipeline drugs)

**Sanofi-Aventis** (coverage of Taxotere, Eloxatine and others)

**Schering-Plough** (coverage of Intron A, Timodar/Temodal, Caelyx/Doxil and pipeline plans)

## Contents

### CHAPTER ONE: EXECUTIVE SUMMARY

- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors

### CHAPTER TWO: INTRODUCTION

- What is Cancer
- Biochemistry of Cancer Cells
- Carcinogen Metabolism
- Causes of Cancer Growth
- Environmental Factors, DNA, RNA
- Cellular Oncogenes
- Tumor Suppressor Genes
- History and Growth of the Cancer Treatment Market
- Growth of Cancer Development
- Industry Structure
- Product Segments and Technology
- Chemotherapy: At a Glance
- Hormone Therapy: At A Glance
- Biotherapy: AT a Glance
- Radiation Therapy: At a Glance
- Demographics and Statistics
- Global Cancer Statistics
- Demographics
- Aging Population
- Life Expectancy and Cancer
- Description of Cancers
- Bladder Cancer

Breast Cancer  
Cervical Cancer  
Colorectal Cancer  
Esophageal Cancer  
Head and Neck  
Kidney  
Leukemia  
Liver  
Lung Cancer  
Lymphoma  
Melanoma  
Multiple Myeloma  
Neuroblastoma  
Ovarian Cancer  
Pancreas  
Prostate Cancer  
Stomach Cancer

### **CHAPTER THREE: CHEMOTHERAPY**

Overview  
Product Descriptions and Examples  
Alkylating Agents  
Antimetabolites  
Cytotoxic Agents  
Plant Derivatives  
Market Size and Growth  
Markets by Product Type  
Markets by Geographical Segments  
U.S. Market  
European Market  
Japan Market  
ROW Market  
Market Data by Indication  
Competitive Analysis

### **CHAPTER FOUR: HORMONE THERAPY**

Overview  
Product Descriptions and Examples  
Corticosteroids  
Synthetic Corticosteroids  
Hormone Agonists and Antagonists  
Estrogens  
Androgens  
Antiestrogens  
Antiandrogens  
Gonadotropin-releasing Hormone Analogues  
Aromatase Inhibitors  
Selective Estrogen Receptor Modulators (SERMs)  
Market Size and Growth  
Markets by Product Type  
Markets by Geographical Segments  
U.S. Market  
Europe Market  
Japan Market  
ROW Market  
Market Data by Indication  
Competitive Analysis

## **CHAPTER FIVE: BIOTHERAPEUTICS**

Overview  
Product Descriptions and Examples  
Monoclonal Antibodies  
Avastin (bevacizumab)  
Campath (alemtuzumab)  
Erbix (cetuximab)  
Herceptin (trastuzumab)  
Mylotarg (gemtuzumab ozogamicin)  
Panorex (edrecolomab)  
Rituxan (rituximab)  
Vectibix (panitumumab)  
Interleukins/Interferons  
Alferon-N  
Infergen

Intron A  
Proleukin  
Roferon A  
Other Biotherapy  
Antisense Oligonucleotides  
Apoptosis  
Growth Factors  
Methylation  
P53  
Ras Protein Drugs  
Regulatory Enzymes  
Proteasome Inhibitors  
Radioimmunotherapy  
Market Size and Growth  
Markets by Product Type  
Markets by Geographical Segments  
U.S. Market  
Europe Market  
Japan Market  
ROW Market  
Market Data by Indication  
Competitive Analysis

## **CHAPTER SIX: WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST**

Overview  
Total Market Size and Forecast  
Competitive Landscape

## **CHAPTER SEVEN: ISSUES AND TRENDS AFFECTING THE CANCER MARKET**

Introduction  
Insurance and Reimbursement Issues  
Cancer Drug Costs  
Personalized Medicine  
Targeted Cancer Therapy  
Pharmacogenomics



Alliances Acquisitions and Licensing Agreements  
Patient-Reported Outcomes  
Alcohol's Affect on Cancer Incidence  
Healthy Lifestyles Continue to Show Promise for  
Cancer Prevention  
Possibility for a Healthier U.S. Population  
Cancer Trends  
Marketing and Distribution Trends  
Geographical Trends  
United States  
Europe  
Japan  
Elderly Clinical Trial Involvement  
Late-Stage Drug Development Trends

## **CHAPTER EIGHT: CORPORATE PROFILES**

Introduction  
AstraZeneca plc  
Biogen IDEC, Inc.  
Bristol-Myers Squibb Company  
Eli Lilly & Company  
Genentech, Inc.  
Johnson & Johnson  
Merck & Company, Inc.  
Novartis AG  
Pfizer, Inc.  
Roche  
Sanofi-Aventis  
Schering-Plough Corporation

## **CHAPTER NINE: COMPANY DIRECTORY**

## **LIST OF EXHIBITS**

## **EXECUTIVE SUMMARY**

Table 1-1 World Cancer Treatment Market,  
2004-2013

Figure 1-1 World Cancer Treatment Market,  
2004-2013

## INTRODUCTION

Table 2-1 Viruses Associated with Cancer in  
Humans

Table 2-2 Cancer Therapy Approvals per Year in  
the United States, 1970-2008

Figure 2-1 Cancer Therapy Approvals per Year in  
the United States, 1970-2008

Table 2-3 Estimated and Projected World Cancer  
Incidence by Selected Types of Cancer, 2007 and  
2020

Figure 2-2 Estimated and Projected World Cancer  
Incidence by Selected Types of Cancer, 2007 and  
2020

Table 2-4 Cancer Incidence and Mortality by  
Country 2007

Figure 2-3 Cancer Incidence by Country 2007

Figure 2-4 Cancer Deaths by Country 2007

Table 2-5 Total Cancer Incidence by Sex and  
Country, 2007

Figure 2-5 Total Cancer Incidence by Sex and  
Country, 2007

Table 2-6 World Population by Selected  
Geographical Region, 2007 - 2050

Figure 2-6 World Population by Selected  
Geographical Region, 2007-2050

Table 2-7 Estimated World Population by Age and  
Geographical Region, 2007

Figure 2-7 Estimated World Population by Age  
and Geographical Region, 2007

Table 2-8 Percent Population Over 65 by Year  
and Region

Figure 2-8 Estimated World Population by Age,  
2007 and 2050

Table 2-9 Average Life Expectancy in Years by Country 1980 and 2008

Figure 2-9 Average Life Expectancy in Years by Country 1980 and 2008

Table 2-10 United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2004

Table 2-11 United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2004

Figure 2-12 Approved Cancer Therapies in the United States by Indication

Table 2-10 Types Of Leukemia

Table 2-11 Types Of Primary Lung Cancer

Table 2-12 Classification Of Non-hodgkin's Lymphomas

Table 2-13 Malignant Conditions Of The Skin

## **CHEMOTHERAPY**

Table 3-1 Leading Products, 2008

Table 3-2 Newly Approved Chemotherapy Agents and Newly Approved Indications, 2007 through 2009

Table 3-3 World Chemotherapy Market, 2004-2013

Figure 3-1 World Chemotherapy Market, 2004-2013

Table 3-4 World Chemotherapy Market, Market by Product Classification, 2004-2013

Figure 3-2 World Chemotherapy Market

Figure 3-3 World Chemotherapy Market

Figure 3-4 World Chemotherapy Market

Figure 3-5 World Chemotherapy Market

Figure 3-6 World Chemotherapy Market

Figure 3-7 World Chemotherapy Market

Table 3-5 World Chemotherapy Market

Figure 3-8 World Chemotherapy Market

Table 3-6 World Chemotherapy Market, Leading

Suppliers Shares by Market Revenues, 2008  
Figure 3-9 World Chemotherapy Market, Leading  
Suppliers Market Share, 2008

## **HORMONE THERAPY**

Table 4-1 Leading Products, 2008

Table 4-2 Newly Approved Hormone Cancer  
Therapies and Additional Indications 2007 through  
2009

Table 4-3 World Hormone Therapy Market,  
2004-2013

Figure 4-1 World Hormone Therapy Market,  
2004-2013

Table 4-4 World Hormone Therapy Market,  
Market by Product Classification, 2004-2013

Figure 4-2 World Hormone Therapy Market,  
Market by Product Classification Revenues,  
2004-2013

Figure 4-3 World Hormone Therapy Market,  
Market by Product Classification and Percent  
Distribution, 2004-2013

Figure 4-4 World Hormone Therapy Market,  
Market by Product Classification and Percent  
Market Share, 2008

Figure 4-5 World Hormone Therapy Market,  
Market by Product Classification and Percent  
Market Share, 2013

Figure 4-5 World Hormone Therapy Market

Figure 4-6 World Hormone Therapy Market

Table 4-6 World Hormone Therapy Market

Figure 4-7 World Hormone Therapy Market

Table 4-7 World Hormone Therapy Market,  
Leading Suppliers Shares by Market Revenues,  
2008

Figure 4-8 World Hormone Therapy Market,  
Leading Suppliers Market Share, 2008

## **BIOTHERAPEUTICS**

Table 5-1 Leading Products, 2008

Table 5-2 Newly Approved Biological Therapies  
and Additional Indications, 2007 through March  
2009

Table 5-3 World Cancer Biotherapeutics Market,  
2004-2013

Figure 5-1 World Cancer Biotherapeutics Market,  
2004-2013

Table 5-4 World Cancer Biotherapeutics Market  
Market by Product Type, (Monoclonal Antibodies,  
Interleukins/ Interferons, Other) 2004-2013

Figure 5-2 World Cancer Biotherapeutics Market,  
Market by Product Classification (Monoclonal  
Antibodies, Interleukins/ Interferons, Other)  
Other Revenues, 2004-2013

Figure 5-3 World Cancer Biotherapeutics Market,  
Market by Product Classification and Percent  
Distribution, 2004-2013

Figure 5-4 World Cancer Biotherapeutics Market,  
Market by Product Classification and Percent  
Market Share, 2008

Figure 5-5 World Cancer Biotherapeutics Market,  
Market by Product Classification and Percent  
Market Share, 2013

Figure 5-6 World Cancer Biotherapeutics Market

Figure 5-7 World Cancer Biotherapeutics Market

Table 5-5 World Cancer Biotherapeutics Market

Figure 5-8 World Cancer Biotherapeutics Market

Table 5-6 World Biotherapeutics Market, Leading  
Suppliers Shares by Market Revenues, 2008

Figure 5-9 World Cancer Biotherapeutics Market,  
Leading Suppliers Market Share, 2008

## **WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST**

Table 6-1 World Cancer Market Market by  
Product Type, 2004-2013

Figure 6-1 World Cancer Market, Market by

Product Type Revenues, 2004-2013

Figure 6-2 World Cancer Market, Market by  
Product Type and Percent Distribution,  
2004-2013

Figure 6-3 World Cancer Market, Market by  
Product Type and Percent Market Share, 2008

Figure 6-4 World Cancer Market, Market by  
Product Type and Percent Market Share, 2013

Table 6-2 World Cancer Market, Top Five  
Suppliers Shares by Market Revenues, 2008

Figure 6-5 World Cancer Market, Top Five  
Suppliers Market Share, 2008 Issues and Trends  
Affecting the Cancer Market

## **ISSUES AND TRENDS AFFECTING THE CANCER MARKET**

Table 7-1 Obesity Rates by State

Table 7-2 Select Products in Development by  
Product Name

Figure 7-1 Late Stage Cancer Compounds in  
Development for Major Indications

## **CORPORATE PROFILES**

Figure 8-1 Late stage Cancer Therapies in  
Development for Leading Companies

## I would like to order

Product name: The World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition

Product link: <https://marketpublishers.com/r/WB4D796FFE8EN.html>

Price: US\$ 3,995.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/WB4D796FFE8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970